Company Overview

Merck & Co., Inc. is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing prescription medicines, vaccines, biologic therapies, and animal health products. The company operates primarily in the pharmaceutical and animal health industries, with research capabilities spanning oncology, infectious diseases, vaccines, cardiometabolic disorders, immunology, and veterinary medicine. Merck generates the majority of its revenue from branded pharmaceutical products, with oncology therapy Keytruda and the Gardasil vaccine franchise serving as major revenue drivers according to recent SEC filings and company annual reports.

The company’s principal business lines include its Pharmaceutical segment and Animal Health segment. Merck serves hospitals, physicians, government agencies, wholesalers, distributors, and veterinary providers across developed and emerging markets. A significant strategic advantage has been its leadership in immuno-oncology through Keytruda, which has become one of the highest-selling prescription drugs globally. Merck traces its U.S. origins to 1891, when it was established as the American subsidiary of the German company Merck KGaA. The company evolved into an independent U.S.-based corporation after World War I and has since expanded through internal research and acquisitions, including the merger with Schering-Plough in 2009.

Business Operations

Merck organizes its operations primarily through the Pharmaceutical and Animal Health business segments. The Pharmaceutical segment develops and markets human health therapeutics and vaccines across oncology, vaccines, infectious diseases, diabetes, cardiovascular disease, and immunology. Major products include Keytruda, Gardasil/Gardasil 9, Januvia, and Winrevair. The Animal Health segment provides veterinary pharmaceuticals, vaccines, health management solutions, and digitally connected livestock monitoring technologies for both companion and production animals.

The company operates manufacturing, research, and commercial facilities across North America, Europe, Asia-Pacific, Latin America, and other international markets. Merck maintains a global research network supported by intellectual property portfolios, biologics manufacturing capabilities, and vaccine production infrastructure. Important subsidiaries and operational entities include Merck Sharp & Dohme LLC, MSD International GmbH, and Merck Animal Health. The company has also established partnerships and licensing arrangements with biotechnology firms, academic institutions, and healthcare organizations to expand its drug pipeline and vaccine development efforts.

Strategic Position & Investments

Merck’s strategic direction has centered on expanding its oncology leadership, advancing vaccine technologies, strengthening its cardiovascular pipeline, and diversifying beyond dependence on Keytruda revenue over the long term. The company has invested heavily in clinical research, biologics manufacturing, and late-stage pipeline development. Recent growth initiatives have included expanded immunotherapy indications, development of personalized medicine approaches, and increased investment in next-generation biologics and antibody-drug conjugates.

Major acquisitions and investments have included the acquisition of Acceleron Pharma, which strengthened Merck’s cardiovascular portfolio through therapies such as Winrevair, and the acquisition of Prometheus Biosciences, which expanded the company’s immunology capabilities. Merck has also pursued licensing and collaboration agreements involving oncology, vaccine platforms, and precision therapeutics. In animal health, the company has expanded digital livestock monitoring and animal intelligence technologies through acquisitions including Antelliq. Public filings and investor materials indicate ongoing investment in mRNA research, immunotherapy combinations, and novel biologic platforms.

Geographic Footprint

Merck is headquartered in Rahway, New Jersey, United States, and operates in more than 140 countries through subsidiaries, manufacturing facilities, research centers, and commercial operations. The company maintains substantial market presence across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. The United States remains its largest single market, although international markets contribute a significant share of total revenue, particularly through vaccine and oncology product sales.

The company’s global operational footprint includes manufacturing and research facilities in countries such as the United States, Ireland, Singapore, the Netherlands, and Japan. Merck also maintains international investment and distribution relationships supporting pharmaceutical access and vaccine deployment in both developed and emerging economies. Its international business is marketed primarily under the MSD brand name outside the United States and Canada due to trademark distinctions involving Germany-based Merck KGaA.

Leadership & Governance

Merck’s leadership structure combines pharmaceutical research expertise, global commercial operations, and scientific innovation management. The company emphasizes research-driven growth, long-term scientific investment, and global health expansion as core elements of its strategic vision. Governance oversight is provided through its board of directors and executive leadership team, with priorities including pipeline development, regulatory compliance, operational execution, and capital allocation discipline.

Key executives include:

• Robert M. Davis – Chairman and Chief Executive Officer
• Caroline Litchfield – Executive Vice President and Chief Financial Officer
• Dean Y. Li – Executive Vice President and President, Merck Research Laboratories
• Frank Clyburn – President, Human Health
• Richard R. DeLuca Jr. – President, Merck Animal Health
• Steven Mizell – Executive Vice President and Chief Human Resources Officer
• Joseph Romanelli – Executive Vice President and General Counsel

Leadership commentary in recent SEC filings, investor presentations, and earnings materials consistently emphasizes scientific innovation, oncology leadership, disciplined business development, and expansion of the company’s diversified product portfolio.